Core Viewpoint - The company is expected to trigger the condition for a downward adjustment of the conversion price of its convertible bonds, "Yifeng Convertible Bonds," due to its stock price being below 85% of the current conversion price for over 10 trading days [2][8]. Group 1: Issuance and Terms of "Yifeng Convertible Bonds" - The company issued 17,974,320 convertible bonds with a total amount of 1,797.4320 million yuan, with a maturity of six years from March 4, 2024, to March 3, 2030 [3]. - The initial conversion price was set at 39.85 yuan per share, which was adjusted to 32.79 yuan on June 7, 2024, and further adjusted to 32.54 yuan on October 15, 2024, due to annual and semi-annual profit distribution [3][4]. Group 2: Conditions for Price Adjustment - The downward adjustment condition states that if the stock price is below 85% of the current conversion price for at least 15 out of 30 consecutive trading days, the board can propose a price adjustment [6]. - The adjusted conversion price must not be lower than the higher of the average stock price over the 20 trading days prior to the shareholders' meeting and the average price on the trading day before the meeting [6]. Group 3: Expected Triggering of Price Adjustment - The period for triggering the price adjustment condition starts from January 16, 2026, to February 2, 2026, during which the stock price must be below 27.06 yuan (85% of 31.84 yuan) for 15 out of 30 trading days [8]. - Upon triggering the condition, the company is required to hold a board meeting to decide on the adjustment and disclose the decision the next trading day [8].

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于预计触发"益丰转债"转股价格向下修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 可转债代码：113682 转债简称：益丰转债 经中国证券监督管理委员会证监许可[2024]109 号文同意注册，公司于 2024 年 3 月 4 日向不特定对象发行了 1,797.4320 万张可转换公司债券，每张面值 100 元，发行总额 179,743.20 万元。债券期限为发行之日起六年（自 2024 年 3 月 4 日至 2030 年 3 月 3 日），债券票面利率为：第一年 0.30%、第二年 0.50%、第 三年 1.00%、第四年 1.50%、第五年 1.80%、第六年 2.00%。2024 年 3 月 27 日， "益丰转债"（债券代码：113682）在上海证券交易所上市 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.02% on February 2, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Individual Stock Performance - The following stocks showed notable performance: - Huaren Health (301408) closed at 21.12, up 0.43% with a trading volume of 177,200 shares and a turnover of 379 million yuan [1] - Dazhenglin (603233) closed at 19.05, down 4.75% with a trading volume of 121,000 shares and a turnover of 235 million yuan [2] - Yifeng Pharmacy (603939) closed at 22.97, down 3.85% with a trading volume of 202,900 shares and a turnover of 472 million yuan [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 208 million yuan from institutional investors, while retail investors had a net inflow of 166 million yuan [2] - The following stocks had significant capital flows: - Yifeng Pharmacy had a net inflow of 52.27 million yuan from institutional investors, but a net outflow of 61.65 million yuan from retail investors [3] - Nanjing Pharmaceutical (600713) had a net inflow of 7.79 million yuan from institutional investors, with a net outflow of 11.72 million yuan from retail investors [3]

Core Insights - The report discusses the development prospects and investment strategies of the Chinese chain pharmacy industry, highlighting key players and market dynamics [1][12]. Industry Overview - The chain pharmacy industry supply chain consists of upstream manufacturers, medical device producers, health product manufacturers, and pharmaceutical logistics suppliers; the midstream is represented by chain pharmacies, while downstream customers include both offline and online clients [1][2]. Key Players - Major listed companies in the chain pharmacy sector include Dazhonglin, Yifeng Pharmacy, and Laobaixing, among others [1][2]. Regional Distribution - Upstream suppliers are primarily located in Beijing, Jiangsu, Hubei, and Hunan, while chain pharmacy operations are concentrated in Hunan, Yunnan, Guangdong, and Shanghai [6]. Financial Performance - By the first half of 2025, three listed chain pharmacy companies, including Guoyao Holdings, Dazhonglin, and Yifeng Pharmacy, are projected to exceed 10 billion yuan in operating revenue, with gross margins above 15%, and Yifeng Pharmacy exceeding 40% [8][9]. Investment Trends - Since 2024, chain pharmacy companies have focused on increasing capital in subsidiaries and acquisitions to improve financial structures and expand sales channels [10]. - Notable investment activities include: - Jianzhijia's capital increase of 466 million yuan across five subsidiaries [11] - Yixintang's investment of 32.8 million yuan in land use rights [11] - Tongrentang's acquisition of a 51% stake in Honghui Pharmaceutical for approximately 10.46 million yuan [11].

发布时间：2026-02-02 行业投资评级 强于大市|维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 8338.3 | | 52 周最高 | 9323.49 | | 52 周最低 | 6876.88 | 行业相对指数表现 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025-02 2025-04 2025-06 2025-09 2025-11 2026-01 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:徐智敏 SAC 登记编号:S1340525100003 Email: xuzhimin@cnpsec.com 近期研究报告 2025 年有数十个 AI 衍生的管线进入人体临床试验，但回顾过往 管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲 折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验 水平的 1 期成功率（80%~90% vs 40%~65%），而在 2 期及后续的进 ...

内容概要：医药终端指的是药品被消费者购买的市场。医药工业是关系国计民生和国家安全的重要产 业。我国是世界工业医药大国，产业链完整，医药产品品种数量、生产能力位居全球前列。近年来，我 国医药工业高质量发展成效显著，医药终端是药品流通的最终交付环节在中国医药市场的广阔天地中， 长久以来，第一终端（公立医院）与第二终端（零售药店）一直占据着舞台的中心。中国药品终端市场 近年来总体保持稳定增长，但增速有所放缓。2025年前三季度，我国医药三大终端六大市场药品销售总 额达到13924亿元，其中，对公立医院终端药品销售额8290亿元，占终端销售额的59.5%；对零售药店 终端药品销售额4385亿元，占终端销售额的31.5%；对公立基层医疗终端药品销售额1249亿元，占终端 销售额的9.0%。 上市企业：益丰药房[603939]、一心堂[002727]、大参林[603233]、老百姓[603883]、漱玉平民 [301017]、健之佳[605266]、达嘉维康 [301126]、华人健康[301408] 2018-2025年前三季度中国医药三大终端六大市场药品销售总额 在中国医药市场的广阔天地中，长久以来，第一终端（公立医 ...

Summary of Key Points from Conference Call Records Industry Overview - **General Economic Outlook**: The Chinese economy shows signs of stabilization, with nominal GDP growth expected to enhance corporate profits. Supply contraction outpacing demand may improve industry prices and corporate earnings, highlighting opportunities in cyclical industries [1][2][3]. Real Estate Sector - **Investment Value**: The real estate sector is deemed to have high investment value, with significant growth in second-hand housing transaction volumes and a narrowing decline in listing prices. Major cities like Beijing and Shanghai have seen listing volumes drop by over 15% [1][3]. - **Policy Catalysts**: Continuous policy support for real estate investment trusts (REITs) and other measures are expected to catalyze the market. The valuation of real estate stocks is considered to have a sufficient margin of safety, with many leading companies trading at a price-to-book (PB) ratio significantly below 1 [1][3][11]. - **Market Dynamics**: The short-term data indicates positive changes in the real estate market, with a notable decrease in listings for older urban properties, as owners prefer renting or waiting for redevelopment rather than selling at lower prices [4][5]. Travel and Transportation Sector - **Positive Outlook**: The travel industry is expected to benefit from government policies promoting tourism, with signs of recovery in duty-free and hotel sectors. The airline industry anticipates strong growth in passenger traffic, with ticket prices expected to be higher than last year [1][8][9]. - **Airline Performance**: During the 2026 Spring Festival travel period, the airline industry is projected to see a 5-6% increase in passenger traffic, with improved ticket pricing compared to 2025. The industry is entering a positive development phase, with a supply growth rate of about 4% and demand growth of approximately 5.5% [9]. Home Appliance Sector - **Investment Opportunities**: The home appliance sector is currently undervalued, presenting good investment opportunities across various segments, including kitchen appliances and white goods. Leading companies are expected to maintain stable performance and high dividend payouts [1][10][11]. Coal Industry - **Market Conditions**: The coal industry is experiencing a marginal improvement in supply-demand dynamics, with a stable price recovery expected. Supply constraints are anticipated to reduce domestic coal supply by 70 million to 100 million tons in 2026, while demand remains resilient [2][19][20]. Chemical Industry - **Future Trends**: The chemical industry is gaining attention due to increased market liquidity and expectations of positive producer price index (PPI) trends. Supply-side constraints and improved demand from global markets are expected to drive price increases [17][18]. Consumer Healthcare Sector - **Recovery Signs**: The consumer healthcare sector is showing early signs of stabilization, particularly in ophthalmology and dental services. Key players in these segments are expected to benefit from a recovering market environment [16]. Food and Beverage Sector - **Market Performance**: The food and beverage sector has seen significant price increases, particularly for premium brands like Moutai. However, potential risks include the release of pent-up supply post-holiday, which could impact prices [21][22]. Construction and Building Materials - **Market Changes**: The construction materials sector is adapting to a shift in demand from new housing to renovations of existing properties. Recent data indicates a recovery in demand for glass and other materials, with expectations of price stabilization and potential increases [24][25]. Conclusion - **Investment Strategy**: Overall, the cyclical industries, particularly real estate, travel, and home appliances, present promising investment opportunities. The focus should be on companies with strong fundamentals and favorable market conditions as the economy stabilizes [1][3][8][11].

肠道健康作为全民健康的重要基石，与多种慢性疾病密切相关。权威数据显示，我国成人慢性便秘患病 率介于4%—6%之间，且随年龄增长呈明显攀升态势，60岁以上人群患病率已突破22%。在"健康中国 2030"战略深入推进的背景下，推动健康管理关口前移、普及肠道健康知识，成为提升全民健康素养的 关键举措。 2026年1月28日，"肠道健康全民行"公益科普活动首次登陆南京，为当地居民带来了一场专业务实、暖 心便捷的公益科普。活动由家庭医生在线与中国药文化研究会国医国药文化传承分会联合主办，江苏益 丰大药房连锁有限公司与南京正大天晴制药有限公司共同支持，延续系列活动"科普助民、服务亲民、 健康惠民"的核心宗旨，将优质医疗资源与健康服务精准下沉至社区，助力居民实现从"被动就医"向"主 动预防"的健康理念转型。 多方聚力发声 共绘健康公益蓝图 活动现场，各方代表通过致辞传递公益初心与责任担当，凝聚起守护社区健康的强大共识。 江苏益丰大药房连锁有限公司总经理吴俊华在致辞中强调，肠道作为人体营养代谢的核心器官和免疫防 御的关键屏障，其健康状况却长期被公众忽视。益丰大药房二十四年来始终秉持"让国人身心更加健 康"的初心，深耕健康领域 ...

Core Viewpoint - The A-share pharmaceutical retail sector is experiencing a significant rebound, driven by a new policy aimed at promoting high-quality development in the industry, which is expected to help around 700,000 pharmacies currently facing challenges [2][3]. Group 1: Industry Trends - The pharmaceutical retail industry is undergoing a wave of closures, with a projected net closure of 39,000 stores in 2024, significantly higher than the 3.8% closure rate in 2023 [5][6]. - The market is witnessing a shift from passive closures to proactive consolidation, as the new policy addresses industry pain points and encourages mergers and acquisitions [2][3][9]. - The concentration of the market is increasing, with the top 10 companies expected to reach a market share of over 35% by 2026, moving towards the levels seen in mature markets [9]. Group 2: Financial Performance - Major players in the industry are facing declining revenues and profits, with companies like YaoYao and GuoDa Pharmacy reporting significant drops in net profits, highlighting the financial strain on the sector [4][5]. - Only one out of six major private listed chains, Yifeng Pharmacy, is expected to achieve positive net profit growth in 2024, indicating a narrowing profitability landscape [5][6]. Group 3: Policy Impact - The new policy aims to standardize and optimize the merger and acquisition process, reducing costs and time for major chains, thus facilitating industry consolidation [7][9]. - The policy encourages a shift from a focus on drug sales to a broader health service model, aligning with changing consumer demands and promoting diversification in product offerings [8][9]. Group 4: Future Outlook - The industry is expected to evolve from merely selling drugs to becoming comprehensive health service providers, enhancing efficiency and better meeting consumer needs [10][11]. - The ongoing transformation is anticipated to eliminate inefficient capacities and elevate industry standards, marking a transition to a new phase of value growth [11].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [3] Core Insights - The recent policy released by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical retail sector is anticipated to see improved performance expectations due to favorable policies, with a recommendation to focus on quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin [6][33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Year-to-date, the pharmaceutical and biotechnology index has increased by 6.66%, outperforming the CSI 300 index by 5.1 percentage points, ranking 16th [11] - The best-performing sub-sector this week was pharmaceutical commerce, which rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] Stock Performance - Among 478 pharmaceutical and biotechnology stocks, 338 stocks increased, representing 70.71% of the total [22] - The top five A-share stocks by performance this week were: *ST Changyao (+70.37%), Hualan Biological Engineering (+32.21%), Kangzhong Medical (+25.47%), Hanshang Group (+20.06%), and Wanze Shares (+19.04%) [22] - In the Hong Kong market, 116 pharmaceutical and biotechnology stocks saw 32 stocks rise, accounting for 27.59% [25] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and optimize industry structure [28] - The FDA granted fast-track designation to CM336, a dual antibody developed by Kangnuo, for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia [31] Recommendations - The report suggests focusing on quality pharmacy enterprises in light of the favorable policies for the pharmaceutical retail sector [33] - It also highlights the potential for vaccine companies in response to the recent Nipah virus cases in India, recommending attention to companies like Zhifei Biological, Kangtai Biological, Watson Bio, and CanSino [34]